𝔖 Bobbio Scriptorium

✦ LIBER ✦

Peginterferon-α-2b associated with serious eye disorders?

Book ID: 120855425
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2004
Weight: 138 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200414560-00050

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon-α-2b + ribavirin effective

Peginterferon-α-2b + ribavirin effective in children with hep C

📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Peginterferon-Α_2B plus ribavirin is mor

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C

✍ E. Villa; C. Cammà; A. Di Leo; A. Karampatou; M. Enea; S. Gitto; V. Bernabucci; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

Serious eye injuries associated with fir

Serious eye injuries associated with fireworks—United states, 1990–1994.: MMWR. 1994;44(24):449-2

✍ Edward A. Walton 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Cutaneous necrosis associated with inter

Cutaneous necrosis associated with interferon α-2b

✍ J.B. Sickler; R.A. Simmons; D.K. Cobb; K.E. Sherman 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 208 KB

Long-term clearance of hepatitis C virus

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

✍ Manns, M. P.; Pockros, P. J.; Norkrans, G.; Smith, C. I.; Morgan, T. R.; Häussin 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Peginterferon alpha-2a is associated wit

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials

✍ Tahany Awad; Kristian Thorlund; Goran Hauser; Davor Stimac; Mahasen Mabrouk; Chr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 1 views

A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is not established which of the two licensed products (peginterferon alpha-2a or peginterferon alfa-2b)